Fusion Pharmaceuticals to Present at Upcoming Investor Conferences - November 8, 2023

2023-11-08

临床1期临床2期

HAMILTON, ON and BOSTON, Nov. 8, 2023 /PRNewswire/ --Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in two upcoming investor conferences. Jefferies London Healthcare Conference – The Company fireside chat presentation will take place on Thursday, November 16, 2023 at 9:00 a.m. GMT. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D. Piper Sandler 35th Annual Healthcare Conference – The Company will participate in the "Radiopharmaceuticals Panel" taking place on Wednesday, November 29, 2023 at 10:00 a.m. ET. Presenting on behalf of Fusion will be Chief Scientific Officer Christopher Leamon, Ph.D. Webcasts of each event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at . A replay of the webcast will be archived on the Company's website for 90 days following their respective presentation dates. About Fusion Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha emitting payloads to tumors. Fusion's clinical portfolio includes: FPI-2265 targeting prostate specific membrane antigen (PSMA) for metastatic castration resistant prostate cancer currently in a Phase 2 trial; FPI-1434 targeting insulin-like growth factor 1 receptor currently in a Phase 1 trial; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1), currently in a Phase 1 trial. In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Response Inhibitors (DDRis) and immuno-oncology agents. The Company recently received IND clearance for FPI-2068, the first novel TAT under the collaboration, which targets EGFR-cMET. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. To support Fusion's growing pipeline of TATs, the Company has signed strategic actinium supply agreements with TRIUMF, Niowave, Inc. and BWXT Medical. Contact: Amanda Cray Senior Director of Investor Relations & Corporate Communications (617) 967-0207 cray@fusionpharma.com Company Codes: NASDAQ-NMS:FUSN

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构